FLUOROPHARMA MEDICAL INC Aktie ..buran und MfG
Anzeige
Meldung des Tages: Schon +250 % im Plus – warum diese Goldstory gerade erst startet!!
FLUOROPHARMA MEDICAL.........
Beiträge:
60
Zugriffe: 10.606 / Heute: 0
Zugriffe: 10.606 / Heute: 0
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
Datum Erster Hoch Tief Schluss Stücke Volumen
06.11.13 0,60 0,60§0,54 0,54 $ 36.740 21.634
GrB
06.11.13 0,60 0,60§0,54 0,54 $ 36.740 21.634
GrB
engages in the discovery, development and commercialization of proprietary medical diagnostic imaging products. The company’s initial focus is the development of breakthrough positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, amyloid plaque in Alzheimer’s disease and agents for detection of certain types of cancer.ir.stockpr.com/fluoropharma/overview
FluoroPharma Medical, Inc. Names GE Healthcare Veteran, Edward L. Lyons, Jr. to Newly Created Position of Vice President, Marketing
Broad Healthcare Industry and Global Experience Will Advance FluoroPharma's Nuclear Cardiology Strategy and Strengthens Goal for Commercialization in 2016
MONTCLAIR, NJ -- (Marketwired) -- 10/28/13 -- FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today that Edward L. Lyons, GE Healthcare's Global Marketing Director, Nuclear Medicine, has been named to FluoroPharma's newly created position of Vice President, Marketing, effective today.
Mr. Lyons will be responsible for the global development and commercial strategy for FluoroPharma's nuclear cardiology portfolio and will report directly to FluoroPharma's Chairman and CEO, Thijs Spoor.
"We are delighted that Ed Lyons, a distinguished healthcare veteran with vast experience in nuclear cardiology across the health care continuum, from hospital to pharmaceuticals and diagnostics; and with the expertise to develop strategic and operational programs that drive growth, has joined our company at such a defining moment in our evolution. Today's announcement reflects the confidence we have in our vision to enable personalized medicine through precision diagnostics, the strength of our science and the promise of our portfolio. We created this position to manage our global strategies, advance our approach to launching, marketing and selling our products as well as strengthening our potential for strategic partnerships," said Mr. Spoor.
"I am excited to be a member of the FluoroPharma team and look forward to contributing to our success. My career has been devoted to diagnostic imaging, and PET is ideal for the early detection and diagnosis of diseases. I believe that the development of new molecular diagnostic imaging agents will extend the utility of PET, while helping to address the global economic challenges of healthcare delivery. FluoroPharma's diagnostics could provide better information for clinicians that will further enable doctors and patients to make more informed choices on treatment. I believe FluoroPharma's pipeline holds great promise, I am confident we have the tools to make the promise become the reality," said Mr. Lyons.
Prior to joining FluoroPharma, Mr. Lyons was with GE Healthcare where he held management positions of increasing responsibility, culminating in his appointment to Global Marketing Director, Nuclear Medicine, where he was responsible for the worldwide marketing of the general purpose, hybrid imaging and direct-conversion detector camera portfolios. During his tenure with GE Healthcare, Mr. Lyons successfully launched AdreView ™ and was responsible for the Cardiology commercial and development portfolios. In 2008, the business received the Frost and Sullivan Award for Radiopharmaceutical Marketing Excellence.
Before GE Healthcare, Mr. Lyons was with Bristol-Myers Squibb Medical Imaging, where he held positions in Medical Affairs Field Operations and Marketing. Prior to Bristol-Myers, Mr. Lyons was with DuPont Pharmaceuticals, where over the span of ten years he held positions in Nuclear Cardiology ranging from Sales and Marketing to Medical Affairs, where he was appointed to Director. Mr. Lyons began his career within the hospital environment, where he was Chief Technologist in Nuclear Medicine and Nuclear Cardiology at Philadelphia Heart Institute, and Temple University Hospital.
Throughout his career, Mr. Lyons has contributed to numerous publications and white papers, and has presented on a variety of medical imaging topics at prestigious industry conferences and meetings.
Mr. Lyons has a diverse educational background in Management Theory and Practice, Marketing Excellence, Strategic Planning and Six Sigma. He holds active board certifications from Temple University School of Nuclear Medicine Technology and Albert Einstein School of Radiologic Technology.
About FluoroPharma Medical
FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The Company has licensed technology from the Massachusetts General Hospital in Boston.
The Company's goal is to enable personalized medicine through precision diagnostics that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.
FluoroPharma's initial focus is the development of breakthrough positron emission tomography (PET) imaging agents and is advancing two products in clinical trials for assessment of acute and chronic forms of coronary artery disease. These first in class agents have been designed to rapidly target myocardial cells. Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image brain tissue affected by Alzheimer's disease and agents that could potentially be used for imaging specific cancers.
In addition to the United States, Europe and China, patents related to FluoroPharma's portfolio of imaging compounds have been issued in Japan, Canada, Australia, Finland, Portugal, Ireland and Mexico.
For more information on the Company, please visit: www.fluoropharma.com
Forward-Looking Statements
Except for historical information contained herein, the statements in this release are forward-looking. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding FluoroPharma's research and development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in FluoroPharma's filings with the United States Securities and Exchange Commission. FluoroPharma undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT:
Media:
Carol Perlman
FluoroPharma Medical, Inc.
cperlman@fluoropharma.com
Phone: 917-592-9260
Investor Relations:
Richard Moyer
Cameron Associates, Inc.
Richard@cameronassoc.com
Phone: 212-554-5466
Source: FluoroPharma Medical, Inc.
Released October 28, 2013
ir.stockpr.com/fluoropharma/company-news/...resident-marketing
Broad Healthcare Industry and Global Experience Will Advance FluoroPharma's Nuclear Cardiology Strategy and Strengthens Goal for Commercialization in 2016
MONTCLAIR, NJ -- (Marketwired) -- 10/28/13 -- FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today that Edward L. Lyons, GE Healthcare's Global Marketing Director, Nuclear Medicine, has been named to FluoroPharma's newly created position of Vice President, Marketing, effective today.
Mr. Lyons will be responsible for the global development and commercial strategy for FluoroPharma's nuclear cardiology portfolio and will report directly to FluoroPharma's Chairman and CEO, Thijs Spoor.
"We are delighted that Ed Lyons, a distinguished healthcare veteran with vast experience in nuclear cardiology across the health care continuum, from hospital to pharmaceuticals and diagnostics; and with the expertise to develop strategic and operational programs that drive growth, has joined our company at such a defining moment in our evolution. Today's announcement reflects the confidence we have in our vision to enable personalized medicine through precision diagnostics, the strength of our science and the promise of our portfolio. We created this position to manage our global strategies, advance our approach to launching, marketing and selling our products as well as strengthening our potential for strategic partnerships," said Mr. Spoor.
"I am excited to be a member of the FluoroPharma team and look forward to contributing to our success. My career has been devoted to diagnostic imaging, and PET is ideal for the early detection and diagnosis of diseases. I believe that the development of new molecular diagnostic imaging agents will extend the utility of PET, while helping to address the global economic challenges of healthcare delivery. FluoroPharma's diagnostics could provide better information for clinicians that will further enable doctors and patients to make more informed choices on treatment. I believe FluoroPharma's pipeline holds great promise, I am confident we have the tools to make the promise become the reality," said Mr. Lyons.
Prior to joining FluoroPharma, Mr. Lyons was with GE Healthcare where he held management positions of increasing responsibility, culminating in his appointment to Global Marketing Director, Nuclear Medicine, where he was responsible for the worldwide marketing of the general purpose, hybrid imaging and direct-conversion detector camera portfolios. During his tenure with GE Healthcare, Mr. Lyons successfully launched AdreView ™ and was responsible for the Cardiology commercial and development portfolios. In 2008, the business received the Frost and Sullivan Award for Radiopharmaceutical Marketing Excellence.
Before GE Healthcare, Mr. Lyons was with Bristol-Myers Squibb Medical Imaging, where he held positions in Medical Affairs Field Operations and Marketing. Prior to Bristol-Myers, Mr. Lyons was with DuPont Pharmaceuticals, where over the span of ten years he held positions in Nuclear Cardiology ranging from Sales and Marketing to Medical Affairs, where he was appointed to Director. Mr. Lyons began his career within the hospital environment, where he was Chief Technologist in Nuclear Medicine and Nuclear Cardiology at Philadelphia Heart Institute, and Temple University Hospital.
Throughout his career, Mr. Lyons has contributed to numerous publications and white papers, and has presented on a variety of medical imaging topics at prestigious industry conferences and meetings.
Mr. Lyons has a diverse educational background in Management Theory and Practice, Marketing Excellence, Strategic Planning and Six Sigma. He holds active board certifications from Temple University School of Nuclear Medicine Technology and Albert Einstein School of Radiologic Technology.
About FluoroPharma Medical
FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The Company has licensed technology from the Massachusetts General Hospital in Boston.
The Company's goal is to enable personalized medicine through precision diagnostics that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.
FluoroPharma's initial focus is the development of breakthrough positron emission tomography (PET) imaging agents and is advancing two products in clinical trials for assessment of acute and chronic forms of coronary artery disease. These first in class agents have been designed to rapidly target myocardial cells. Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image brain tissue affected by Alzheimer's disease and agents that could potentially be used for imaging specific cancers.
In addition to the United States, Europe and China, patents related to FluoroPharma's portfolio of imaging compounds have been issued in Japan, Canada, Australia, Finland, Portugal, Ireland and Mexico.
For more information on the Company, please visit: www.fluoropharma.com
Forward-Looking Statements
Except for historical information contained herein, the statements in this release are forward-looking. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding FluoroPharma's research and development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in FluoroPharma's filings with the United States Securities and Exchange Commission. FluoroPharma undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT:
Media:
Carol Perlman
FluoroPharma Medical, Inc.
cperlman@fluoropharma.com
Phone: 917-592-9260
Investor Relations:
Richard Moyer
Cameron Associates, Inc.
Richard@cameronassoc.com
Phone: 212-554-5466
Source: FluoroPharma Medical, Inc.
Released October 28, 2013
ir.stockpr.com/fluoropharma/company-news/...resident-marketing
CONSOLIDATED BALANCE SHEETS (USD $)
§
Jun. 30, 2013
§
Dec. 31, 2012
Current Assets:
Cash and cash equivalents $ 65,935 $ 1,304,088
Prepaid expenses & other 30,711 77,310
Total Current Assets 96,646 1,381,398
Property and equipment, net 168,709 176,889
Intangible assets, net 52,293 55,247
Total Assets 317,648 1,613,534
Current Liabilities:
Accounts payable 339,827 137,779
Notes Payable - Stockholders 200,000
Accrued expenses 34,134 97,728
Total Current Liabilities 573,961 235,507
Stockholders' Equity (Deficit):
Preferred stock Series A - $0.001 par value, 3,500,000 designated 2,234,673 and 2,126,574 shares issued and outstanding at June 30, 2013 and at December 31, 2012, respectively (preference in liquidation of $1,854,779 at June 30, 2013) 2,236 2,127
Common stock - Class A - $0.001 par value, 200,000,000 shares authorized, 24,375,013 and 24,330,013 shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively 24,376 24,331
Additional paid-in capital 18,786,302 18,242,109
Deficit accumulated in the development stage (19,069,227) (16,890,540)
Total Stockholders' Equity (Deficit) (256,313) 1,378,027
Total Liabilities and Stockholders' Equity (Deficit) $ 317,648 $ 1,613,534
ir.stockpr.com/fluoropharma/financials
§
Jun. 30, 2013
§
Dec. 31, 2012
Current Assets:
Cash and cash equivalents $ 65,935 $ 1,304,088
Prepaid expenses & other 30,711 77,310
Total Current Assets 96,646 1,381,398
Property and equipment, net 168,709 176,889
Intangible assets, net 52,293 55,247
Total Assets 317,648 1,613,534
Current Liabilities:
Accounts payable 339,827 137,779
Notes Payable - Stockholders 200,000
Accrued expenses 34,134 97,728
Total Current Liabilities 573,961 235,507
Stockholders' Equity (Deficit):
Preferred stock Series A - $0.001 par value, 3,500,000 designated 2,234,673 and 2,126,574 shares issued and outstanding at June 30, 2013 and at December 31, 2012, respectively (preference in liquidation of $1,854,779 at June 30, 2013) 2,236 2,127
Common stock - Class A - $0.001 par value, 200,000,000 shares authorized, 24,375,013 and 24,330,013 shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively 24,376 24,331
Additional paid-in capital 18,786,302 18,242,109
Deficit accumulated in the development stage (19,069,227) (16,890,540)
Total Stockholders' Equity (Deficit) (256,313) 1,378,027
Total Liabilities and Stockholders' Equity (Deficit) $ 317,648 $ 1,613,534
ir.stockpr.com/fluoropharma/financials
3:57 PM EST Nov 6, 2013
Last Price
0.54
§
Change $
0.06
§
Change %
10.00%
§
Tick
N/A
Bid
N/A
§
Bid Size
0
§
Ask
N/A
§
Ask Size
0
Open
0.60
§
High
0.60
§
Low
0.54
§
Prev Close
0.60
Last Trade
3:57
§
Volume
36.74k
§
52 Wk Hi
0.95
§
52 Wk Low
0.51
Market Cap
13.17m
§
Ex-Div Date
N/A
§
Div Rate
N/A
§
Yield
N/A
Shares
24,380,013
§
EPS (TTM)
-0.15
§
PE Ratio
N/A
§
Exchange
OTCBB
ir.stockpr.com/fluoropharma/quote
Last Price
0.54
§
Change $
0.06
§
Change %
10.00%
§
Tick
N/A
Bid
N/A
§
Bid Size
0
§
Ask
N/A
§
Ask Size
0
Open
0.60
§
High
0.60
§
Low
0.54
§
Prev Close
0.60
Last Trade
3:57
§
Volume
36.74k
§
52 Wk Hi
0.95
§
52 Wk Low
0.51
Market Cap
13.17m
§
Ex-Div Date
N/A
§
Div Rate
N/A
§
Yield
N/A
Shares
24,380,013
§
EPS (TTM)
-0.15
§
PE Ratio
N/A
§
Exchange
OTCBB
ir.stockpr.com/fluoropharma/quote
Zeit Kurs Stück
21:34:05§0,56 $ 2.500
_____________________
GRATULATION
21:34:05§0,56 $ 2.500
_____________________
GRATULATION
::::::::::::::: 0,56 $ +3,70% +0,02 $ In Euro: 0,4177 € | Nasdaq OTC BB, 07.11.13 ,GrB
Zeit Kurs Stück
15:51:28§0,55 $ 4.000
_____________________
GRATULATION
15:51:28§0,55 $ 4.000
_____________________
GRATULATION
Zeit
Kurs Stück §
18:34:31§0,52 $
20.000 §
18:12:32§0,52 $
20.000 §
17:36:06§0,52 $
20.000 §
16:01:22§0,50 $
50.000 §
16:01:16§0,50 $
§50.000
Kosmonova buran
Kurs Stück §
18:34:31§0,52 $
20.000 §
18:12:32§0,52 $
20.000 §
17:36:06§0,52 $
20.000 §
16:01:22§0,50 $
50.000 §
16:01:16§0,50 $
§50.000
Kosmonova buran
Zeit
Kurs Stück §
17:47:46§0,51 $
225 §
17:02:53§0,50 $
8.487 §
16:28:40§0,51 $
1.000 §
16:28:10§0,51 $
4.000 §
16:17:18§0,50 $
20.600 §
16:12:41§0,51 $
§1.000
buran und THX und weitermachen
Kurs Stück §
17:47:46§0,51 $
225 §
17:02:53§0,50 $
8.487 §
16:28:40§0,51 $
1.000 §
16:28:10§0,51 $
4.000 §
16:17:18§0,50 $
20.600 §
16:12:41§0,51 $
§1.000
buran und THX und weitermachen
Zeit
Kurs Stück §
17:45:54§0,52 $
19.500 §
15:37:30§0,58 $
1.000 §
15:35:10§0,58 $
1.000 §
15:34:42§0,58 $
§3.400
buran und MfG
Kurs Stück §
17:45:54§0,52 $
19.500 §
15:37:30§0,58 $
1.000 §
15:35:10§0,58 $
1.000 §
15:34:42§0,58 $
§3.400
buran und MfG
Datum Erster Hoch Tief Schluss Stücke Volumen
18.11.13 0,57 0,57§0,57 0,57 $ 3.300 1.881
GrB
18.11.13 0,57 0,57§0,57 0,57 $ 3.300 1.881
GrB
Datum Erster Hoch Tief Schluss Stücke Volumen
20.11.13 0,57 0,57 0,57 0,57 $ 700 399
GrB
20.11.13 0,57 0,57 0,57 0,57 $ 700 399
GrB
::::::::::::: 0,575 $ +0,88% +0,005 $
In Euro: 0,4242 € | Nasdaq OTC BB, 22.11.13 ,GrB
In Euro: 0,4242 € | Nasdaq OTC BB, 22.11.13 ,GrB
Zeit
Kurs Stück §
21:42:38§0,575 $
1.000 §
20:50:18§0,56 $
1.000 §
20:49:21§0,56 $
9.000 §
19:27:00§0,58 $
700 §
16:30:13§0,58 $
100
_____________
GRATULATION
Kurs Stück §
21:42:38§0,575 $
1.000 §
20:50:18§0,56 $
1.000 §
20:49:21§0,56 $
9.000 §
19:27:00§0,58 $
700 §
16:30:13§0,58 $
100
_____________
GRATULATION
Datum Erster Hoch Tief Schluss Stücke Volumen
25.11.13 0,58 0,58§0,56 0,575 $ 11.800 6.639
GrB
25.11.13 0,58 0,58§0,56 0,575 $ 11.800 6.639
GrB
Zeit
Kurs Stück §
19:07:12§0,58 $
10.000 §
18:11:03§0,60 $
1.600 §
17:45:11§0,60 $
2.800 §
17:45:08§0,58 $
2.200 §
16:59:43§0,58 $
1.765 §
15:36:10§0,575 $
9.235
Kosmonova buran und MfG und danke und weitermachen
Kurs Stück §
19:07:12§0,58 $
10.000 §
18:11:03§0,60 $
1.600 §
17:45:11§0,60 $
2.800 §
17:45:08§0,58 $
2.200 §
16:59:43§0,58 $
1.765 §
15:36:10§0,575 $
9.235
Kosmonova buran und MfG und danke und weitermachen
::::::::::::::::: 0,58 $ +0,87% +0,005 $
In Euro: 0,4266 € | Nasdaq OTC BB, 26.11.13 ,GrB
In Euro: 0,4266 € | Nasdaq OTC BB, 26.11.13 ,GrB
0.58 0.01(0.87%) Nov 26, 2:39PM EST|Pre-Market : NaN
Prev Close: 0.57
Open:0.57
Bid: N/A§
Ask:§N/A
1y Target Est: 1.20
Beta:§-0.01
Next Earnings Date: N/A
Day's Range: 0.57 - 0.60
52wk Range: 0.48 - 0.95
Volume:§31,509
Avg Vol (3m): 26,012
Market Cap: 14.15M
P/E (ttm): N/A
EPS (ttm): -0.25
Div & Yield: N/A (N/A)
finance.yahoo.com/q?s=fpmi&ql=1
Prev Close: 0.57
Open:0.57
Bid: N/A§
Ask:§N/A
1y Target Est: 1.20
Beta:§-0.01
Next Earnings Date: N/A
Day's Range: 0.57 - 0.60
52wk Range: 0.48 - 0.95
Volume:§31,509
Avg Vol (3m): 26,012
Market Cap: 14.15M
P/E (ttm): N/A
EPS (ttm): -0.25
Div & Yield: N/A (N/A)
finance.yahoo.com/q?s=fpmi&ql=1
29-Oct-2013
Other Events, Financial Statements and Exhibits
Item 8.01. Other Events.
On October 28, 2013, FluoroPharma Medical, Inc. (the "Company") announced that Edward L. Lyons, GE Healthcare's Global Marketing Director, Nuclear Medicine, has been named to the Company's newly created position of Vice President, Marketing, effective as of October 28, 2013.
The press release relating to the foregoing is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Item 9.01. Financial Statement and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release dated October 28, 2013.
biz.yahoo.com/e/131029/fpmi8-k.html
Other Events, Financial Statements and Exhibits
Item 8.01. Other Events.
On October 28, 2013, FluoroPharma Medical, Inc. (the "Company") announced that Edward L. Lyons, GE Healthcare's Global Marketing Director, Nuclear Medicine, has been named to the Company's newly created position of Vice President, Marketing, effective as of October 28, 2013.
The press release relating to the foregoing is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Item 9.01. Financial Statement and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release dated October 28, 2013.
biz.yahoo.com/e/131029/fpmi8-k.html
14-Nov-2013
Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
This report contains forward-looking statements. These forward-looking statements include, without limitation, statements containing the words "believes","anticipates","expects","intends","projects","will" and other words of similar import or the negative of those terms or expressions. Forward-looking statements in this report include, but are not limited to, expectations of future levels of research and development spending, general and administrative spending, levels of capital expenditures and operating results, sufficiency of our capital resources, our intention to pursue and consummate strategic opportunities available to us.. Forward-looking statements are subject to certain known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to those described in "Risk Factors" of the reports we file with the SEC.
Overview
We are a biopharmaceutical company specializing in discovering, developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. Molecular imaging pharmaceuticals are radiopharmaceuticals that enable early detection of disease through the visualization of subtle changes in biochemical and biological processes. We currently have two clinical-stage molecular imaging pharmaceutical product candidates: CardioPET and BFPET. Additionally we have identified potential candidates that may be useful in the detection and/or treatment of vulnerable plaque.
biz.yahoo.com/e/131114/fpmi10-q.html
Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
This report contains forward-looking statements. These forward-looking statements include, without limitation, statements containing the words "believes","anticipates","expects","intends","projects","will" and other words of similar import or the negative of those terms or expressions. Forward-looking statements in this report include, but are not limited to, expectations of future levels of research and development spending, general and administrative spending, levels of capital expenditures and operating results, sufficiency of our capital resources, our intention to pursue and consummate strategic opportunities available to us.. Forward-looking statements are subject to certain known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to those described in "Risk Factors" of the reports we file with the SEC.
Overview
We are a biopharmaceutical company specializing in discovering, developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. Molecular imaging pharmaceuticals are radiopharmaceuticals that enable early detection of disease through the visualization of subtle changes in biochemical and biological processes. We currently have two clinical-stage molecular imaging pharmaceutical product candidates: CardioPET and BFPET. Additionally we have identified potential candidates that may be useful in the detection and/or treatment of vulnerable plaque.
biz.yahoo.com/e/131114/fpmi10-q.html
By Brian Marckx, CFA
Q3 2013 10-Q Filed
FluoroPharma (OTC BB:FPMI) filed their 10-Q for the third quarter ending September 30, 2013. Aside from operating expenses continuing to come in beneficially lower than our numbers, results remain mostly in-line with our estimates. Cash burn also remains within our expectations.
Q3 operating expenses were $900k, about $200k lower than Q2 and about one-half as much as our $1.8 million estimate. We continue to expect operating expenses to increase with clinical trials progression. Q3 net loss to common and EPS were $2.5 million and ($0.10) but excluding $1.35 million accounted for as non-cash preferred dividends ("deemed dividend") related to revaluation of the conversion feature of the recently issued Series B preferred stock, net loss to common and EPS were $1.2 million and ($0.05), compared to our $1.9 million loss and ($0.07) estimates.
Cash used in operating activities was $564k in Q3, down from $765k in Q2. Cash burn is averaging about $670k/quarter in 2013, down from about $825k/quarter in 2012.
finance.yahoo.com/news/...ndustry-veteran-hired-130000423.html
Q3 2013 10-Q Filed
FluoroPharma (OTC BB:FPMI) filed their 10-Q for the third quarter ending September 30, 2013. Aside from operating expenses continuing to come in beneficially lower than our numbers, results remain mostly in-line with our estimates. Cash burn also remains within our expectations.
Q3 operating expenses were $900k, about $200k lower than Q2 and about one-half as much as our $1.8 million estimate. We continue to expect operating expenses to increase with clinical trials progression. Q3 net loss to common and EPS were $2.5 million and ($0.10) but excluding $1.35 million accounted for as non-cash preferred dividends ("deemed dividend") related to revaluation of the conversion feature of the recently issued Series B preferred stock, net loss to common and EPS were $1.2 million and ($0.05), compared to our $1.9 million loss and ($0.07) estimates.
Cash used in operating activities was $564k in Q3, down from $765k in Q2. Cash burn is averaging about $670k/quarter in 2013, down from about $825k/quarter in 2012.
finance.yahoo.com/news/...ndustry-veteran-hired-130000423.html
to the Medical Imaging & Technology Alliance (MITA)
MONTCLAIR, NJ--(Marketwired - November 25, 2013) - FluoroPharma Medical, Inc. (FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today that it has been elected to MITA and will be represented by Edward L. Lyons, Vice President of Marketing. Mr. Lyons is responsible for the global development and commercial strategy for FluoroPharma's nuclear cardiology portfolio.
MITA, a division of the National Electrical Manufacturers Association (NEMA), is the leading organization and collective voice of medical imaging equipment, radiation therapy and radiopharmaceutical manufacturers, innovators and product developers. It represents companies whose sales comprise more than 90 percent of the global market for medical imaging technology.
"FluoroPharma is pleased and proud to become a member of this important organization. MITA is a key advocate for our industry as medical diagnostic products are playing an ever increasing role in the detection, diagnosis and treatment of disease. We are delighted to have Ed Lyons represent both our company as well as cardiac patients' interests at MITA," said FluoroPharma's Chairman and CEO Thijs Spoor.
"The policy landscape for diagnostics has become more complicated. Diagnostics are highly valued, therefore highly utilized," said Mr. Lyons. "Because they are highly utilized, they are the subject of far more scrutiny than in the past. We believe that as a member company of MITA, we will share in the collective knowledge, experience, and support of the Molecular Imaging community to develop our diagnostic products in a way that clearly demonstrates their clinical and economic value in cardiovascular disease."
About FluoroPharma Medical
FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The Company has licensed technology from the Massachusetts General Hospital in Boston.
The Company's goal is to enable personalized medicine through precision diagnostics that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.
FluoroPharma's initial focus is the development of breakthrough positron emission tomography (PET) imaging agents and is advancing two products in clinical trials for assessment of acute and chronic forms of coronary artery disease. These first in class agents have been designed to rapidly target myocardial cells. Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image brain tissue affected by Alzheimer's disease and agents that could potentially be used for imaging specific cancers.
In addition to the United States, Europe and China, patents related to FluoroPharma's portfolio of imaging compounds have been issued in Japan, Canada, Australia, Finland, Portugal, Ireland and Mexico.
For more information on the Company, please visit: www.fluoropharma.com
Forward-Looking Statements
Except for historical information contained herein, the statements in this release are forward-looking. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding FluoroPharma's research and development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in FluoroPharma's filings with the United States Securities and Exchange Commission. FluoroPharma undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
CONTACT:
Media:
Carol J. Perlman
FluoroPharma Medical, Inc.
cperlman@fluoropharma.com
Phone: 917-592-9260
Investor Relations:
Richard Moyer
Cameron Associates, Inc.
Richard@cameronassoc.com
Phone: 212-554-5466
finance.yahoo.com/news/...l-inc-elected-medical-145352615.html
MONTCLAIR, NJ--(Marketwired - November 25, 2013) - FluoroPharma Medical, Inc. (FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today that it has been elected to MITA and will be represented by Edward L. Lyons, Vice President of Marketing. Mr. Lyons is responsible for the global development and commercial strategy for FluoroPharma's nuclear cardiology portfolio.
MITA, a division of the National Electrical Manufacturers Association (NEMA), is the leading organization and collective voice of medical imaging equipment, radiation therapy and radiopharmaceutical manufacturers, innovators and product developers. It represents companies whose sales comprise more than 90 percent of the global market for medical imaging technology.
"FluoroPharma is pleased and proud to become a member of this important organization. MITA is a key advocate for our industry as medical diagnostic products are playing an ever increasing role in the detection, diagnosis and treatment of disease. We are delighted to have Ed Lyons represent both our company as well as cardiac patients' interests at MITA," said FluoroPharma's Chairman and CEO Thijs Spoor.
"The policy landscape for diagnostics has become more complicated. Diagnostics are highly valued, therefore highly utilized," said Mr. Lyons. "Because they are highly utilized, they are the subject of far more scrutiny than in the past. We believe that as a member company of MITA, we will share in the collective knowledge, experience, and support of the Molecular Imaging community to develop our diagnostic products in a way that clearly demonstrates their clinical and economic value in cardiovascular disease."
About FluoroPharma Medical
FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The Company has licensed technology from the Massachusetts General Hospital in Boston.
The Company's goal is to enable personalized medicine through precision diagnostics that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.
FluoroPharma's initial focus is the development of breakthrough positron emission tomography (PET) imaging agents and is advancing two products in clinical trials for assessment of acute and chronic forms of coronary artery disease. These first in class agents have been designed to rapidly target myocardial cells. Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image brain tissue affected by Alzheimer's disease and agents that could potentially be used for imaging specific cancers.
In addition to the United States, Europe and China, patents related to FluoroPharma's portfolio of imaging compounds have been issued in Japan, Canada, Australia, Finland, Portugal, Ireland and Mexico.
For more information on the Company, please visit: www.fluoropharma.com
Forward-Looking Statements
Except for historical information contained herein, the statements in this release are forward-looking. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding FluoroPharma's research and development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in FluoroPharma's filings with the United States Securities and Exchange Commission. FluoroPharma undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
CONTACT:
Media:
Carol J. Perlman
FluoroPharma Medical, Inc.
cperlman@fluoropharma.com
Phone: 917-592-9260
Investor Relations:
Richard Moyer
Cameron Associates, Inc.
Richard@cameronassoc.com
Phone: 212-554-5466
finance.yahoo.com/news/...l-inc-elected-medical-145352615.html
Market Cap (intraday)5: 14.15M
Enterprise Value (Nov 27, 2013)3: 10.59M
Trailing P/E (ttm, intraday): N/A
Forward P/E (fye Dec 31, 2014)1: N/A
PEG Ratio (5 yr expected)1: N/A
Price/Sales (ttm): N/A
Price/Book (mrq): 17.97
Enterprise Value/Revenue (ttm)3: NaN
Enterprise Value/EBITDA (ttm)6: -2.42
finance.yahoo.com/q/ks?s=FPMI+Key+Statistics
Enterprise Value (Nov 27, 2013)3: 10.59M
Trailing P/E (ttm, intraday): N/A
Forward P/E (fye Dec 31, 2014)1: N/A
PEG Ratio (5 yr expected)1: N/A
Price/Sales (ttm): N/A
Price/Book (mrq): 17.97
Enterprise Value/Revenue (ttm)3: NaN
Enterprise Value/EBITDA (ttm)6: -2.42
finance.yahoo.com/q/ks?s=FPMI+Key+Statistics
Fiscal Year
Fiscal Year Ends: Dec 31
Most Recent Quarter (mrq): Sep 30, 2013
Profitability
Profit Margin (ttm): N/A
Operating Margin (ttm): N/A
Management Effectiveness
Return on Assets (ttm): -115.86%
Return on Equity (ttm): -512.93%
Income Statement
Revenue (ttm): N/A
Revenue Per Share (ttm): N/A
Qtrly Revenue Growth (yoy): N/A
Gross Profit (ttm): N/A
EBITDA (ttm)6: -4.37M
Net Income Avl to Common (ttm): -6.09M
Diluted EPS (ttm): -0.25
Qtrly Earnings Growth (yoy): N/A
Balance Sheet
Total Cash (mrq): 3.37M
Total Cash Per Share (mrq): 0.14
Total Debt (mrq): 55.00K
Total Debt/Equity (mrq): 6.98
Current Ratio (mrq): 1.20
Book Value Per Share (mrq): 0.03
Cash Flow Statement
Operating Cash Flow (ttm): -2.83M
Levered Free Cash Flow (ttm): 856.66K
finance.yahoo.com/q/ks?s=FPMI+Key+Statistics
Fiscal Year Ends: Dec 31
Most Recent Quarter (mrq): Sep 30, 2013
Profitability
Profit Margin (ttm): N/A
Operating Margin (ttm): N/A
Management Effectiveness
Return on Assets (ttm): -115.86%
Return on Equity (ttm): -512.93%
Income Statement
Revenue (ttm): N/A
Revenue Per Share (ttm): N/A
Qtrly Revenue Growth (yoy): N/A
Gross Profit (ttm): N/A
EBITDA (ttm)6: -4.37M
Net Income Avl to Common (ttm): -6.09M
Diluted EPS (ttm): -0.25
Qtrly Earnings Growth (yoy): N/A
Balance Sheet
Total Cash (mrq): 3.37M
Total Cash Per Share (mrq): 0.14
Total Debt (mrq): 55.00K
Total Debt/Equity (mrq): 6.98
Current Ratio (mrq): 1.20
Book Value Per Share (mrq): 0.03
Cash Flow Statement
Operating Cash Flow (ttm): -2.83M
Levered Free Cash Flow (ttm): 856.66K
finance.yahoo.com/q/ks?s=FPMI+Key+Statistics
a: -0.01
52-Week Change3: -20.55%
S&P500 52-Week Change3: 27.86%
52-Week High (Jan 3, 2013)3: 0.95
52-Week Low (Nov 11, 2013)3: 0.48
50-Day Moving Average3: 0.59
200-Day Moving Average3: 0.64
finance.yahoo.com/q/ks?s=FPMI+Key+Statistics
52-Week Change3: -20.55%
S&P500 52-Week Change3: 27.86%
52-Week High (Jan 3, 2013)3: 0.95
52-Week Low (Nov 11, 2013)3: 0.48
50-Day Moving Average3: 0.59
200-Day Moving Average3: 0.64
finance.yahoo.com/q/ks?s=FPMI+Key+Statistics
Avg Vol (3 month)3: 26,012
Avg Vol (10 day)3: 7,371
Shares Outstanding5: 24.39M
Float:§16.49M
% Held by Insiders1: N/A
% Held by Institutions1: N/A
Shares Short 3: N/A
Short Ratio 3: N/A
Short % of Float 3: N/A
Shares Short (prior month)3: N/A
finance.yahoo.com/q/ks?s=FPMI+Key+Statistics
Avg Vol (10 day)3: 7,371
Shares Outstanding5: 24.39M
Float:§16.49M
% Held by Insiders1: N/A
% Held by Institutions1: N/A
Shares Short 3: N/A
Short Ratio 3: N/A
Short % of Float 3: N/A
Shares Short (prior month)3: N/A
finance.yahoo.com/q/ks?s=FPMI+Key+Statistics
finance.yahoo.com/q/rr?s=FPMI+Research+Reports GrB
company, discovers, develops, and commercializes medical diagnostic imaging products to evaluate cardiac disease at the cellular and molecular levels. The company focuses on the development of positron emission tomography (PET) imaging agents for the detection and assessment of acute and chronic forms of coronary artery disease. It offers PET scan imaging agents that include CardioPET, a modified fatty acid that provides insight into regions with decreased blood flow or metabolic insufficiency in the myocardium; BFPET, a flourine-18 labeled tracer that enters the myocardial cells in direct proportion to blood flow and cell membrane potential; VasoPET, an imaging agent that targets active molecule receptors associated with inflammatory conditions to visualize areas in the blood vessels that may initiate thrombosis and embolism; and AZPET, an imaging agent that attaches to amyloid deposits (plaque) in the brain and makes them visible on a PET scan for the early detection of Alzheimer’s disease. The company serves molecular imaging, cardiovascular, and other diagnostic markets in the United States, Canada, Mexico, China, Japan, and Australia; and Finland, Portugal, Ireland, and other European countries through stock brokers and online trading accounts. FluoroPharma Medical, Inc. was formerly known as FluoroPharma, Inc. and changed its name to FluoroPharma Medical, Inc. in May 2011. The company was founded in 2003 and is headquartered in Montclair, New Jersey.
finance.yahoo.com/q/pr?s=FPMI+Profile
finance.yahoo.com/q/pr?s=FPMI+Profile
Website: www.fluoropharma.com
buran und MfG und schüddelböööööön
buran und MfG und schüddelböööööön
:::::::::::::::::: 0,60 $ +3,45% +0,02 $
In Euro: 0,4412 € | Nasdaq OTC BB, 27.11.13 ,GrB
In Euro: 0,4412 € | Nasdaq OTC BB, 27.11.13 ,GrB
Datum Erster Hoch Tief Schluss Stücke Volumen
29.11.13 0,60 0,60§0,60 0,60 $ 2.000 1.200
GrB
29.11.13 0,60 0,60§0,60 0,60 $ 2.000 1.200
GrB
Zeit Kurs Stück
21:54:20§0,59 $ 10.000
_____________________
GRATULATION
21:54:20§0,59 $ 10.000
_____________________
GRATULATION
Zeit Kurs Stück
18:21:56§0,55 $ 555
18:17:43§0,55 $ 600
17:57:22§0,57 $ 5.000
17:02:08§0,57 $ 11.500
17:02:00§0,5503 $ 5.000
buran und MfG und danke und TOP
18:21:56§0,55 $ 555
18:17:43§0,55 $ 600
17:57:22§0,57 $ 5.000
17:02:08§0,57 $ 11.500
17:02:00§0,5503 $ 5.000
buran und MfG und danke und TOP
Datum Erster Hoch Tief Schluss Stücke Volumen
15.01.14 0,70 0,72§0,65 0,65 $ 319.007 212 T
14.01.14 0,72 0,72§0,66 0,70 $ 198.575 136 T
13.01.14 0,75 0,76§0,67 0,68 $ 293.030 204 T
10.01.14 0,60 0,76§0,55 0,76 $ 197.728 105 T
09.01.14 0,57 0,59§0,5201 0,5201 $ 30.422 17.204
08.01.14 0,5701 0,59§0,55 0,55 $ 45.900 25.953
07.01.14 0,59 0,59§0,59 0,59 $ 5.000 2.950
06.01.14 0,58 0,58§0,58 0,58 $ 3.600 2.088
03.01.14 0,60 0,60§0,55 0,5701 $ 24.820 14.034
02.01.14 0,6399 0,6399§0,60 0,60 $ 13.468 8.287
GrB
15.01.14 0,70 0,72§0,65 0,65 $ 319.007 212 T
14.01.14 0,72 0,72§0,66 0,70 $ 198.575 136 T
13.01.14 0,75 0,76§0,67 0,68 $ 293.030 204 T
10.01.14 0,60 0,76§0,55 0,76 $ 197.728 105 T
09.01.14 0,57 0,59§0,5201 0,5201 $ 30.422 17.204
08.01.14 0,5701 0,59§0,55 0,55 $ 45.900 25.953
07.01.14 0,59 0,59§0,59 0,59 $ 5.000 2.950
06.01.14 0,58 0,58§0,58 0,58 $ 3.600 2.088
03.01.14 0,60 0,60§0,55 0,5701 $ 24.820 14.034
02.01.14 0,6399 0,6399§0,60 0,60 $ 13.468 8.287
GrB
Datum Erster Hoch Tief Schluss Stücke Volumen
17.01.14 0,70 0,70§0,66 0,68 $ 122.800 83 T
GrB
17.01.14 0,70 0,70§0,66 0,68 $ 122.800 83 T
GrB
::::::::::::::::: 0,67 $ +3,08% +0,02 $
In Euro: 0,4966 € | Nasdaq OTC BB, 31.01.14:::::::: Kosmonova buran und MfG und danke und SCHICK
In Euro: 0,4966 € | Nasdaq OTC BB, 31.01.14:::::::: Kosmonova buran und MfG und danke und SCHICK
Datum Erster Hoch Tief Schluss Stücke Volumen
28.02.14 0,56 0,60§0,536 0,54 $ 279.735 155 T
27.02.14 0,525 0,57§0,51 0,57 $ 313.750 168 T
26.02.14 0,541 0,55§0,51 0,51 $ 145.556 77 T
25.02.14 0,55 0,57§0,531 0,55 $ 179.409 92 T
24.02.14 0,561 0,561§0,531 0,55 $ 123.427 68 T
21.02.14 0,551 0,56§0,531 0,55 $ 109.500 60 T
20.02.14 0,561 0,58§0,551 0,551 $ 67.590 38.129
19.02.14 0,57 0,578§0,551 0,551 $ 116.235 66 T
18.02.14 0,54 0,60§0,54 0,55 $ 64.317 36.050
14.02.14 0,53 0,54§0,51 0,52 $ 148.280 77 T
13.02.14 0,51 0,53§0,4701 0,53 $ 150.760 75 T
12.02.14 0,52 0,53§0,51 0,51 $ 118.930 62 T
11.02.14 0,522 0,54§0,51 0,52 $ 326.070 172 T
10.02.14 0,55 0,57§0,508 0,549 $ 208.747 114 T
07.02.14 0,59 0,59§0,535 0,55 $ 315.027 173 T
06.02.14 0,64 0,69§0,52 0,60 $ 450.617 280 T
05.02.14 0,635 0,64§0,621 0,64 $ 107.120 68 T
04.02.14 0,64 0,68§0,623 0,63 $ 360.766 236 T
03.02.14 0,67 0,67§0,63 0,63 $ 92.416 55 T
buran und MfG und danke und weitermachen
28.02.14 0,56 0,60§0,536 0,54 $ 279.735 155 T
27.02.14 0,525 0,57§0,51 0,57 $ 313.750 168 T
26.02.14 0,541 0,55§0,51 0,51 $ 145.556 77 T
25.02.14 0,55 0,57§0,531 0,55 $ 179.409 92 T
24.02.14 0,561 0,561§0,531 0,55 $ 123.427 68 T
21.02.14 0,551 0,56§0,531 0,55 $ 109.500 60 T
20.02.14 0,561 0,58§0,551 0,551 $ 67.590 38.129
19.02.14 0,57 0,578§0,551 0,551 $ 116.235 66 T
18.02.14 0,54 0,60§0,54 0,55 $ 64.317 36.050
14.02.14 0,53 0,54§0,51 0,52 $ 148.280 77 T
13.02.14 0,51 0,53§0,4701 0,53 $ 150.760 75 T
12.02.14 0,52 0,53§0,51 0,51 $ 118.930 62 T
11.02.14 0,522 0,54§0,51 0,52 $ 326.070 172 T
10.02.14 0,55 0,57§0,508 0,549 $ 208.747 114 T
07.02.14 0,59 0,59§0,535 0,55 $ 315.027 173 T
06.02.14 0,64 0,69§0,52 0,60 $ 450.617 280 T
05.02.14 0,635 0,64§0,621 0,64 $ 107.120 68 T
04.02.14 0,64 0,68§0,623 0,63 $ 360.766 236 T
03.02.14 0,67 0,67§0,63 0,63 $ 92.416 55 T
buran und MfG und danke und weitermachen
:::::::::::::::::: 0,72 $ +0,70% +0,005 $
In Euro: 0,5219 € | Nasdaq OTC BB, 21.03.14::::: und Du bist nicht dabei... boaa ..::Kosmonova buran ..::hopshopshopshopshopshops HALLO
In Euro: 0,5219 € | Nasdaq OTC BB, 21.03.14::::: und Du bist nicht dabei... boaa ..::Kosmonova buran ..::hopshopshopshopshopshops HALLO
Datum Erster Hoch Tief Schluss Stücke Volumen
16.05.14 0,743 0,747§0,735 0,735 $ 21.578 15.955
GrB
16.05.14 0,743 0,747§0,735 0,735 $ 21.578 15.955
GrB
Datum Erster Hoch Tief Schluss Stücke Volumen
05.08.14 0,56 0,59§0,56 0,56 $ 54.715 31.405
GrB
05.08.14 0,56 0,59§0,56 0,56 $ 54.715 31.405
GrB
::::::::::::: 0,60 $ +3,45% +0,02 $
In Euro: 0,4666 € | Nasdaq OTC Other, 18.09.14:::::: Bouche
In Euro: 0,4666 € | Nasdaq OTC Other, 18.09.14:::::: Bouche
buran: nur ein börsenboard geführt von www.bundesbank.de 21:18 #1
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/…/nur-ein-boersenboard-gefuehrt-von-www…
Deutsche Bundesbank - Startseite
Die Deutsche Bundesbank ist die Zentralbank der Bundesrepublik Deutschland. Zentrales Geschäftsfeld ist die Geldpolitik des Eurosystems.
BUNDESBANK.DE
https://www.facebook.com/mario.meierhof
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/…/nur-ein-boersenboard-gefuehrt-von-www…
Deutsche Bundesbank - Startseite
Die Deutsche Bundesbank ist die Zentralbank der Bundesrepublik Deutschland. Zentrales Geschäftsfeld ist die Geldpolitik des Eurosystems.
BUNDESBANK.DE
https://www.facebook.com/mario.meierhof
Abkürzung für Federal Openmarket Committee
http://www.ariva.de/extras/lexikon.m?begriff=FOMC
http://www.ariva.de/extras/lexikon.m?begriff=FOMC
Datum Erster Hoch Tief Schluss Stücke Volumen
13.02.15 0,385 0,385§0,36 0,38 $ 87.500 33.021
GrB
13.02.15 0,385 0,385§0,36 0,38 $ 87.500 33.021
GrB
Datum Erster Hoch Tief Schluss Stücke Volumen
13.03.15 0,48 0,4848§0,46 0,48 $ 19.300 9.289
GrB
13.03.15 0,48 0,4848§0,46 0,48 $ 19.300 9.289
GrB
GESAMT-ROUNDUP: CeBIT träumt vom 'digitalen Wirtschaftswunder'
20:31 15.03.15
HANNOVER (dpa-AFX) - Die Digitalisierung der Wirtschaft sorgt für Hoffnung und Angst auf der CeBIT. IT-Schwergewichte versprechen in Hannover das "digitale Wirtschaftswunder", warnen aber zugleich davor, dass deutsche Firmen abgehängt werden könnte. "Wer jetzt nicht die Weichen für die Zukunft stellt, ist schnell vom Markt verschwunden", mahnte der Präsident des Branchenverbands Bitkom, Dieter Kempf, am Sonntag zum Start der weltgrößten IT-Messe. "In der Wirtschaft wird kein Stein auf dem anderen bleiben." http://www.ariva.de/news/...t-vom-digitalen-Wirtschaftswunder-5310441
20:31 15.03.15
HANNOVER (dpa-AFX) - Die Digitalisierung der Wirtschaft sorgt für Hoffnung und Angst auf der CeBIT. IT-Schwergewichte versprechen in Hannover das "digitale Wirtschaftswunder", warnen aber zugleich davor, dass deutsche Firmen abgehängt werden könnte. "Wer jetzt nicht die Weichen für die Zukunft stellt, ist schnell vom Markt verschwunden", mahnte der Präsident des Branchenverbands Bitkom, Dieter Kempf, am Sonntag zum Start der weltgrößten IT-Messe. "In der Wirtschaft wird kein Stein auf dem anderen bleiben." http://www.ariva.de/news/...t-vom-digitalen-Wirtschaftswunder-5310441
Zeit Kurs Stück
15:39:46§0,3499 $ 200
15:38:29§0,3311 $ 500
15:37:58§0,34 $ 2.500
_____________________
GRATULATION
15:39:46§0,3499 $ 200
15:38:29§0,3311 $ 500
15:37:58§0,34 $ 2.500
_____________________
GRATULATION
::::::::::: 0,25 $ +4,17% +0,01 $
In Euro: 0,2253 € | 27.06.16 Nasdaq OTC Other ,GrB
In Euro: 0,2253 € | 27.06.16 Nasdaq OTC Other ,GrB
:::::::::: 0,2449 $ +8,31% +0,0188 $
In Euro: 0,2161 € | 15.08.16 Nasdaq OTC Other ,GrB
In Euro: 0,2161 € | 15.08.16 Nasdaq OTC Other ,GrB
FluoroPharma and Philips Collaborate on Image Management for CardioPET Phase II Clinical Trial
Oct 18 2016, 11:00 AM EDT www.fluoropharma.com/
Oct 18 2016, 11:00 AM EDT www.fluoropharma.com/
FluoroPharma Medical, Inc. (FPMI) is a publicly traded biopharmaceutical company engaged in the discovery, development and commercialization of proprietary medical diagnostic imaging products. www.fluoropharma.com/investor-relations/...information/profile
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem FLUOROPHARMA MEDICAL Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 59 | FLUOROPHARMA MEDICAL......... | buran | buran | 25.04.21 02:53 |